Krsnaa Diagnostics liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2.86×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.68×2.68×1.36×1.50×2.28×
2.59×2.59×1.26×1.37×2.02×
30.230.23.82.422.7
463463109140127
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health
₹ CrorePeersSURAKSHAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,615 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————2.86
Current Ratio2.281.501.362.682.68
Quick Ratio2.021.371.262.592.59
Cash, Equiv & ST Investments22.72.43.830.230.2
Working Capital126.6139.7109.1463.1463.1
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.